ReviewAgeing research reviews2016
Cystatin C in aging and in Alzheimer's disease.
Review in Ageing research reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Pooled it
- Aberrant Levels of Cystatin C in Amyotrophic Lateral Sclerosis: a Systematic Review and Meta Analysis.International journal of biological sciences · 2018Pooled it
- Cystatin C and its Role in the Neuro-Glial-Vascular Unit: Implications for Cerebrovascular Diseases and Neurodegeneration.Neuroscience bulletin · 2026Review
- A Comparative Study of Plasma Biomarkers of Neurodegeneration in Rhesus Monkeys (bioRxiv : the preprint server for biology · 2026Article
- Proteomic health archetypes identified in disease-free adults enable risk assessment for diverse chronic diseases.Genome medicine · 2026Article
- Aging-associated modulation of UFMylation impairs proteostasis in C. elegans.Nature communications · 2026Article
- Causality relationship between 91 inflammatory factors and Alzheimer disease: A bidirectional Mendelian randomization study.Medicine · 2026Article
- Relationship between serum cystatin C and long-term mortality in patients with self-reported COPD: evidence from two large population-based surveys.BMJ open respiratory research · 2026Article
- A spatially informed matrix normal model for gene co-expression analysis in spatial transcriptomics studies.Nucleic acids research · 2025Article
- Asparagine endopeptidase (AEP) inhibitor formulation via zein-based nanoparticle improves the therapeutic efficacy toward Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Genetic Correlations and Causalities between Alzheimer's Disease and 35 Biomarkers in Blood and Urine.Molecular neurobiology · 2025Article
- Association of Serum Cystatin C with Stroke Morbidity and All-Cause and Cardio-Cerebrovascular Mortality: Evidence from the NHANES.Healthcare (Basel, Switzerland) · 2025Article
- Aggrecan protects against plaque accumulation and is essential for proper microglial responses to plaques.Cell reports · 2025Article
- MicroRNA-140-5p and cystatin-C expression in patients with vascular cognitive impairment and its clinical value.Biomarkers in medicine · 2025Article
- Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Value of blood biomarkers in the diagnosis of Parkinson's disease: a case-control study from Xinjiang.BMC neurology · 2025Article
- Association of cystatin C kidney function measures with motoric cognitive risk syndrome: evidence from two cohort studies.The journal of nutrition, health & aging · 2025Article
- The Predictive Power of the Cystatin C-Creatinine Score in Assessing Frailty.Journal of cachexia, sarcopenia and muscle · 2025Article
- Investigation of serum cystatin C levels and their diagnostic value in combination with inflammatory ratios in patients with bipolar disorder.Frontiers in psychiatry · 2025Article
- Endosomal traffic disorders: a driving force behind neurodegenerative diseases.Translational neurodegeneration · 2024Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Under normal conditions, the function of catalytically active proteases is regulated, in part, by their endogenous inhibitors, and any change in the synthesis and/or function of a protease or its endogenous inhibitors may result in inappropriate protease activity. Altered proteolysis as a result of an imbalance between active proteases and their endogenous inhibitors can occur during normal aging, and such changes have also been associated with multiple neuronal diseases, including Amyotrophic Lateral Sclerosis (ALS), rare heritable neurodegenerative disorders, ischemia, some forms of epilepsy, and Alzheimer's disease (AD). One of the most extensively studied endogenous inhibitor is the cysteine-protease inhibitor cystatin C (CysC). Changes in the expression and secretion of CysC in the brain have been described in various neurological disorders and in animal models of neurodegeneration, underscoring a role for CysC in these conditions. In the brain, multiple in vitro and in vivo findings have demonstrated that CysC plays protective roles via pathways that depend upon the inhibition of endosomal-lysosomal pathway cysteine proteases, such as cathepsin B (Cat B), via the induction of cellular autophagy, via the induction of cell proliferation, or via the inhibition of amyloid-β (Aβ) aggregation. We review the data demonstrating the protective roles of CysC under conditions of neuronal challenge and the protective pathways induced by CysC under various conditions. Beyond highlighting the essential role that balanced proteolytic activity plays in supporting normal brain aging, these findings suggest that CysC is a therapeutic candidate that can potentially prevent brain damage and neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.